Advanced Ovarian Cancer
Conditions
Brief summary
To compare dose-dense chemotherapy with intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.
Detailed description
Women aged 20 and above, diagnosed with advanced stage ovarian cancer (FIGO stage II\ IV), who had received debulking surgery, followed by adjuvant chemotherapy (either dose-dense or intraperitoneal) at our institution between 01 January 2006 and 31 December 2018 were included in the study. Patient characteristics, any treatment related side-effects (peri-operative and post-operative complications, chemotherapy related adverse events), treatment response (complete or partial response, stable disease or progressive disease), post-treatment surveillance (disease status: disease-free, recurrence or cancer-related death) will be recorded. Univariate and multivariate logistic regression analysis will be employed to evaluate the survival benefit of the two different chemotherapy methods.
Interventions
Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy
Sponsors
Far Eastern Memorial Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women with FIGO stage II\ IV ovarian cancer * At least one cycle of intravenous dose-dense or intraperitoneal chemotherapy had been administered as the front-line chemotherapy.
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survivals between this intraveous and intraperitoneal chemotherapy groups | 10 years | months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survivals between this two groups | 10 years | months |
Countries
Taiwan
Outcome results
None listed